Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland
暂无分享,去创建一个
[1] M. Nassisi,et al. Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration , 2023, BMC Ophthalmology.
[2] V. Sheth,et al. New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD) , 2021, Journal of clinical medicine.
[3] Rishi P. Singh,et al. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. , 2021, Ophthalmology.
[4] P. Rosenfeld,et al. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan. , 2021, American journal of ophthalmology.
[5] H. Heimann,et al. Impact of COVID-19 pandemic on eye cancer care in United Kingdom , 2021, British Journal of Cancer.
[6] A. Kam,et al. Reduction in Ophthalmic Presentations to Australian Emergency Departments During the COVID-19 Period: Are We Seeing the Full Picture? , 2021, Clinical ophthalmology.
[7] Philip J Rosenfeld,et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. , 2020, Ophthalmology.
[8] Jeany Q. Li,et al. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis , 2019, British Journal of Ophthalmology.
[9] F. Kronenberg,et al. On the impact of different approaches to classify age-related macular degeneration: Results from the German AugUR study , 2018, Scientific Reports.
[10] F. Kronenberg,et al. On the impact of different approaches to classify age-related macular degeneration: Results from the German AugUR study , 2018, Scientific Reports.
[11] A. Lotery,et al. Genetics and genetic testing for age-related macular degeneration , 2018, Eye.
[12] A. Tuulonen,et al. The Finnish national guideline for diagnosis, treatment and follow‐up of patients with wet age‐related macular degeneration , 2017, Acta ophthalmologica.
[13] Yara T. E. Lechanteur,et al. Nature Genetics Advance Online Publication , 2022 .
[14] R. Klein,et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.
[15] J. Sahel,et al. Risk factors for exudative age-related macular degeneration in a large French case–control study , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.
[16] Richard Wormald,et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. , 2012, Ophthalmology.
[17] C. Bunce,et al. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008 , 2010, Eye.
[18] A. Reunanen,et al. Prevalence of major eye diseases and causes of visual impairment in the adult Finnish population: a nationwide population‐based survey , 2009, Acta ophthalmologica.
[19] L. Laatikainen,et al. Prevalence and visual consequences of macular changes in a population aged 70 years and older. , 2009, Acta ophthalmologica Scandinavica.
[20] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[21] E. Chew,et al. Age-Related Macular Degeneration: Epidemiology and Clinical Aspects. , 2021, Advances in experimental medicine and biology.
[22] Imre,et al. Prevalence of Age-Related Macular Degeneration in Europe The Past and the Future , 2017 .
[23] A. Ramé. [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.